Toxicity of muscimol and ibotenic acid containing mushrooms reported to a regional poison control center from 2002–2016

Abstract Background: Amanita muscaria (AM) and A. pantherina (AP) contain ibotenic acid and muscimol and may cause both excitatory and sedating symptoms. Gastrointestinal (GI) symptoms are not classically described but have been reported. There are relatively few reported cases of poisoning with these mushrooms in North America. Methods: This is a retrospective review of ingestions of ibotenic acid and muscimol containing mushrooms reported to a United States regional poison center from 2002–2016. Cases were included if identification was made by a mycologist or if AM was clearly described. Results: Thirty-four cases met inclusion criteria. There were 23 cases of AM, 10 AP, and 1 A. aprica. Reason for ingestion included foraging (12), recreational (6), accidental (12), therapeutic (1), self-harm (1), and unknown (2). Of the accidental pediatric ingestions 4 (25%) were symptomatic. None of the children with a symptomatic ingestion of AM required admission. A 3-year-old male who ingested AP had vomiting, agitation, and lethargy and received benzodiazepines. He was intubated and had a 3-day ICU stay. There were 25 symptomatic patients. All but one patient developed symptoms within 6 h. Six patients had symptoms for less than 6 h while 15 had symptoms lasting less than 24 h. Ingestions of AP were more symptomatic than AM with regard to the presence of any GI symptoms (80% vs. 35%), central nervous system (CNS) depression (70% vs. 35%), and CNS excitation (70% vs. 35%) respectively. Five patients were intubated. No patients experienced hypotension, seizures, acute kidney injury, or hepatotoxicity. No deaths were reported. Discussion: Ingestion of ibotenic acid/muscimol containing mushrooms often produces a syndrome with GI upset, CNS excitation, and CNS depression either alone or in combination. Ingestion of AP was associated with a higher rate of symptoms compared to AM.

[1]  D. Spyker,et al.  2016 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 34th Annual Report , 2017, Clinical toxicology.

[2]  M. Brvar,et al.  Amanita muscaria and Amanita pantherina poisoning: two syndromes. , 2014, Toxicon : official journal of the International Society on Toxinology.

[3]  B. Horowitz,et al.  Amanita smithiana mushroom ingestion: A case of delayed renal failure and literature review , 2009, Journal of Medical Toxicology.

[4]  K. Kuwayama,et al.  Analysis of hallucinogenic constituents in Amanita mushrooms circulated in Japan. , 2006, Forensic science international.

[5]  M. Bunc,et al.  Prolonged psychosis after Amanita muscaria ingestion , 2006, Wiener klinische Wochenschrift.

[6]  D. Pach,et al.  Panther cap Amanita pantherina poisoning case report and review. , 2006, Toxicon : official journal of the International Society on Toxinology.

[7]  C. Tanaka,et al.  Molecular phylogeny and biogeography of the widely distributed Amanita species, A. muscaria and A. pantherina. , 2004, Mycological research.

[8]  D. Benjamin Mushroom poisoning in infants and children: the Amanita pantherina/muscaria group. , 1992, Journal of toxicology. Clinical toxicology.

[9]  M. Saar Ethnomyocological data from Siberia and North-East Asia on the effect of Amanita muscaria. , 1991, Journal of ethnopharmacology.

[10]  J. Ammirati,et al.  Poisonous mushrooms of the northern United States and Canada , 1985 .

[11]  W. Chilton,et al.  Toxic metabolites of Amanita pantherina, A. cothurnata, A. muscaria and other Amanita species. , 1976, Lloydia.

[12]  J. Ott Psycho-Mycological Studies Of Amanita – From Ancient Sacrament To Modern Phobia , 1976 .

[13]  D. R. Curtis,et al.  Central actions of ibotenic acid and muscimol. , 1968, Biochemical pharmacology.

[14]  C. H. Eugster Über Muscarin aus Fliegenpilzen. 2. Mitteilung über Muscarin , 1956 .